After teaching a client with a fractured humerus, the nurse assesses the client’s understanding. Which dietary choice demonstrates that the client correctly understands the nutrition needed to assist in healing the fracture?

Choice A reason: Methotrexate typically takes 6–12 weeks to achieve therapeutic effects in rheumatoid arthritis by suppressing immune-mediated inflammation. Stating 1–2 weeks is inaccurate, as it underestimates the time needed for the drug to modulate immune response and reduce joint inflammation.
Choice B reason: Discussing cost and pharmacy plans is not a priority in health teaching about methotrexate’s clinical effects. While cost may be a concern, it is not relevant to the drug’s pharmacological action or patient safety education.
Choice C reason: Methotrexate is an immunosuppressant, reducing immune response to control RA inflammation. This increases infection risk, as immune cells like neutrophils are suppressed. Avoiding crowds minimizes exposure to pathogens, making this a critical and appropriate teaching point for patient safety.
Choice D reason: Alcohol consumption, even in moderation (2–3 glasses of wine weekly), is discouraged with methotrexate due to its hepatotoxic effects. Alcohol exacerbates liver damage risk, as methotrexate is metabolized by the liver, potentially leading to elevated liver enzymes or hepatotoxicity.

Choice A reason: The wearing-off phenomenon in Parkinson’s occurs when levodopa’s effect diminishes before the next dose, causing symptom fluctuations. This results from progressive dopamine neuron loss, reducing storage capacity, and shorter levodopa half-life, leading to rapid swings in motor control as plasma levels fluctuate.
Choice B reason: Intolerance to medications may cause side effects (e.g., nausea), but the wearing-off phenomenon is due to disease progression and levodopa’s pharmacokinetics, not patient tolerance. Symptoms return as drug levels drop, not because of inability to tolerate the dose.
Choice C reason: Medications like levodopa remain effective, but wearing-off occurs due to shorter duration of action as Parkinson’s progresses, not loss of drug efficacy. Neuron loss reduces dopamine storage, causing symptoms to re-emerge between doses, not a failure of the drug itself.
Choice D reason: The liver metabolizes levodopa minimally; carbidopa prevents peripheral breakdown. Wearing-off is due to central nervous system changes (loss of dopamine neurons), not liver dysfunction, which does not significantly alter levodopa’s pharmacokinetics in Parkinson’s disease.